Bacteriophages Therapy is a highly innovative form of complementary medicine. It is a treatment that involves the use of bacteria to heal the body. It can be effective in fighting viruses, infections, and diseases including influenza, viral arthritis, HIV, hepatitis, and cancer. In fact, studies have shown that when patients are treated with bacteriophages they have higher recovery rates and have lower complications than those who have remained untreated. The demand for bacteriophages has increased over the years with increase in cases of foodborne diseases. These foodborne diseases typically occur due to food spoilage. As per the World Health Organization (WHO), around 600 million cases of foodborne diseases and 420,000 deaths are recorded each year globally. As per the same source, 30% of foodborne deaths occur in children aged 5 years and below. Such factors can potentially augment growth of the bacteriophages therapy market.
Fatigue is a common symptom of both sinus and throat infections. Fatigue is often the first sign that the patient will experience and often other symptoms will follow such as nasal congestion, headache, fever, and the sensation that there is something "handed" within the nose. For this reason, Bacteriophages Therapy can be an extremely effective treatment and can help relieve many of the symptoms associated with an infection. Since there is high demand for these types of therapies, extensive research and development activities have been carried out. Key companies in the pharmaceutical and healthcare industries are focused on rigorous R&D activities, in order to come up with novel therapies and drugs. Thus, such activities can further stimulate growth of the bacteriophages therapy market in the near future.
Recently, in January 2021, Armata Pharmaceuticals, Inc., a U.S.-based biotechnology company, announced to invest US$ 20 million to support the advancement of the company’s bacteriophages development programs.
Developed economies including the U.S. seem to be witnessing sharp growth in regards to the bacteriophages therapy market. This is typically due to that there is a high prevalence of foodborne diseases. As per the Centers for Disease Control and Prevention (CDC), around 48 million people get sick and 3,000 die from foodborne diseases each year in the U.S. On the contrary, Asia Pacific is exhibiting promising signs in the bacteriophages therapy market with the launch of new products.
That being said, there are certain aspects of this therapy that can limit its adoption on the global scale. Bacteriophages therapy is expensive and requires high-cost clinical testing with a high risk of product failure. Besides, physicians are required to have special training, in order to prescribe and use phages. Hence, such factors can impede growth of the bacteriophages therapy market in the near future.
No comments:
Post a Comment